DGAP-News

Carl Zeiss Meditec Recruits James V. Mazzo to Lead its Newly Consolidated Ophthalmology Organization

DGAP-News: Carl Zeiss Meditec AG / Key word(s): Change of Personnel
Carl Zeiss Meditec Recruits James V. Mazzo to Lead its Newly Consolidated
Ophthalmology Organization

27.07.2016 / 09:00
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Carl Zeiss Meditec Recruits James V. Mazzo to Lead its Newly Consolidated
Ophthalmology Organization

Carl Zeiss Meditec AG consolidates its ophthalmology activities in a single
Strategic Business Unit; James V. Mazzo will head the new ophthalmology
division.


Jena, Germany, July 27th, 2016
Carl Zeiss Meditec AG has been expanding its ophthalmology business over
the last years. Today, it has the broadest line of diagnostic and surgical
products in the industry. Consolidating the product lines into a single
Strategic Business Unit led by a proven, experienced leader will facilitate
more effective customer service, more aggressive market penetration and
global expansion.

James V. Mazzo will join Carl Zeiss Meditec as Global President of
Ophthalmology with responsibility for the new Strategic Business Unit
Ophthalmology as well as Carl Zeiss Meditec's U.S. Sales and Service
Center. Jim Mazzo is one of the industry's best known and most respected
business leaders with over 35 years of ophthalmic experience. He spent over
20 years leading Allergan's North American and European eye care
organizations. He led the public spin-off of AMO as Chairman/CEO, built
that organization into a leading company in refractive, cataract and eye
care products. In 2009 Abbott Labs purchased AMO and Mazzo was selected as
EVP to lead Abbott's global ophthalmology business. He left Abbott in 2013
to become executive chair and CEO of AcuFocus and Executive Chair of
Neurotech.

In a joint statement by Executive and Supervisory Board of Carl Zeiss
Meditec AG, Dr. Ludwin Monz, President & CEO, and Dr. Michael Kaschke,
Chairman of the Supervisory Board, comment: "We are excited to have Mr.
Mazzo, one of the best experts in the ophthalmology industry join the ZEISS
family. The re-organization and new leadership of the ophthalmology
business will allow Carl Zeiss Meditec to extend the offering for
ophthalmology and optometric customers globally. We see particular
opportunities in extending the business in North America and parts of
Asia."

"I am privileged and honored to be joining Carl Zeiss Meditec. The company
has been an innovative leader in the industry for over 100 years. The broad
line of technology and commitment to our industry is exciting. I look
forward to continuing this excellence and building ZEISS into the premier
ophthalmic franchise," says James V. Mazzo.

Carl Zeiss Meditec AG is listed on TecDAX of the German stock exchange and
based in Jena, Germany. In fiscal year 2014/15 it achieved revenues of 1.04
bn EUR. The ZEISS Group owns 65% of the shares and the majority of Carl
Zeiss Meditec AG. The ZEISS Group reached revenues of 4.5 bn EUR in the
same fiscal year.

Contact for the press
Alice Swinton
Director Global Communications, Carl Zeiss Meditec Inc.
Office: [phone]
[e-mail]

Contact for investors
Sebastian Frericks
Director Investor Relations Carl Zeiss Meditec AG
Phone: [phone]
Email: [e-mail]
www.zeiss.com/press






---------------------------------------------------------------------------

27.07.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de

---------------------------------------------------------------------------

Language: English
Company: Carl Zeiss Meditec AG
Göschwitzer Str. 51-52
07745 Jena
Germany
Phone: [phone]
Fax: [phone]
E-mail: [e-mail],[e-mail]
Internet: www.meditec.zeiss.de
ISIN: DE0005313704
WKN: 531370
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange; Terminbörse EUREX


End of News DGAP News Service
---------------------------------------------------------------------------

486415 27.07.2016